BRIEF-Intellia And Regeneron Announce Clinical Data For NTLA-2001

Reuters2021-06-26

June 26 (Reuters) - Regeneron Pharmaceuticals Inc :

* INTELLIA AND REGENERON ANNOUNCE LANDMARK CLINICAL DATA SHOWING DEEP REDUCTION IN DISEASE-CAUSING PROTEIN AFTER SINGLE INFUSION OF NTLA-2001, AN INVESTIGATIONAL CRISPR THERAPY FOR TRANSTHYRETIN (ATTR) AMYLOIDOSIS

* REGENERON PHARMACEUTICALS - INTERIM READOUT IN ONGOING PHASE 1 TRIAL FINDS SINGLE 0.3 MG/KG DOSE OF NTLA-2001 LED TO 87% MEAN REDUCTION IN SERUM TTR

* NO SERIOUS ADVERSE EVENTS OBSERVED IN FIRST SIX PATIENTS BY DAY 28

Source text for Eikon: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

免责声明:本文观点仅代表作者个人观点,不构成本平台的投资建议,本平台不对文章信息准确性、完整性和及时性做出任何保证,亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

  • SKYK
    2021-06-27
    SKYK
    Intla!
发表看法
1